| HOME >> BIOLOGY >> TECHNOLOGY |
Net loss $(9,376) $(11,394)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization 3,129 2,558
Amortization of intangible assets 2,310 2,050
Amortization of prepaid compensation expense 126 125
Stock-based compensation related to employees
and consulting services rendered 6,968 4,299
Deferred rent 376 8
Changes in operating assets and liabilities:
Accounts receivable 2,690 (6,884)
Inventory (4,419) (5,352)
Prepaid expenses and other current assets (1,239) (764)
Other non-current assets (161) 210
Accounts payable and other current
liabilities 5,333 545
Income taxes payable (213) -
Accrued compensation (210) 393
Accrued expense for patent-related matter - (3,350)
Deferred revenue (1,348) 1,921
Net cash provided by (used in)
operating activities 3,966 (15,635)
Cash flows from investing activities:
Capital expenditures (9,000) (2,955)
Payments for technology licenses - (4,737)
Cost of Sangtec acquisition, net of cash
acquired - (27,341)
Proceeds from maturities of marketable
| SOURCE Cepheid Copyright©2008 PR Newswire. All rights reserved |